Prot #CRG‐022‐101: An Open‐label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG‐022, a CD22‐Directed Autologous Chimeric Antigen Receptor (CAR) T‐cell Therapy in Patients With Relapsed/Refractory Large B‐Cell Lymphoma After CD19‐Dire

Project: Research project

Project Details

StatusActive
Effective start/end date5/24/245/24/27

Funding

  • Novella Clinical, LLC (Prot #CRG-022-101 // Prot #CRG-022-101)
  • CARGO Therapeutics, Inc. (Prot #CRG-022-101 // Prot #CRG-022-101)